Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Safety and PK of Oral TP-271 in Healthy Adults
NCT03450187Phase 1Completed
- Sponsor
- Tetraphase Therapeutics
- Start
- Mar 2018
- Primary completion
- Dec 2018
- Modality
- Orthosteric Ligands
- Countries
- 1
01
Overview
Phase 1, randomised, double-blind trial of TP-271 in bacterial infection, community-acquired bacterial pneumonia (CAP), anthrax and 2 more (6 arms), sponsored by Tetraphase Therapeutics. Primary endpoints: Adverse Events, Directed Physical Examination and 3 more. Started Mar 2018; status: completed.
02
Drugs
TP-271
03
Conditions
bacterial infectioncommunity-acquired bacterial pneumonia (CAP)anthraxtularemiaplague
Beyond the preview
Go deeper on NCT03450187.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT03450187.